We aspire to end the suffering of each patient and work with the healthcare community to ensure that no-one is left behind
In Conversation
For pharmaceutical companies, the HK-GBA early access program could serve as a valuable testing ground in GBA for their market launch strategies in mainland China
From a practical angle, the quality of the investigators, doctors and academics in Hong Kong is as good as you will find anywhere else in the…
In China, the ophthalmology market is expected to grow from USD 1.8 billion in 2015 to USD 20.2 billion by 2030 ... a 17.5 percent increase…
Current methods [of cancer testing] often detect cancer at later stages through protein markers. Our aim is to revolutionize this by introducing early cancer detection, starting…
In just five years we have built an Asian hub for international biotechnology listings in Hong Kong
I feel that the region is ready to bring in [gene] therapies, both in terms of regulatory affairs as well as pricing schemes
With the amount of data available through Hong Kong's Hospital Authority database, precision and personalised medicine could be a good focus for the city
The business model offered by NewBridge is becoming more relevant and a mainstay in the industry across emerging markets, not just MENA
I believe it is our responsibility as the market leaders in Hong Kong to shape the ecosystem
There are over 100 VC funds in Southern China, so there is plenty of opportunity for these young companies, and we have participated in co-funding
Thanks to generative AI we can double Big Pharma’s R&D productivity in a very small biotech setting
